A compound of formula (II): ** Formula ** stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof, wherein: Ar is C6-C10 aryl substituted by 0-5 R3； C5-C10 cycloalkenyl substituted by 0-5 R3； or 5-14 membered heteroaryl group substituted with 0-5 R3, wherein said heteroaryl group comprises one, two, or three heteroatoms selected from N, O, S or Se； Y is -CH2-, -CH (OCH3) -, or -CH2CH2-； R1 is C (>； = O) NR12R13； R2 is selected from H, F, Cl, Br, I, OR16, OR25, NR17R18, NHOH, NO2, CN, CF3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C (>； = O) R16 , C (>； = O) OR16, OC (>； = O) R16, C (>； = O) NR17R18, NR15C (>； = O) R16, NR15CO2R16, OC (>； = O) NR17R18, NR15C (>； = S) R16 , SR16； S (>； = O) R16； and S (>； = O) 2R16； alternatively, two R2groups can be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group； R3 is selected from H, F, Cl, Br, I, OR16, OCF3, OR25, NR17R18, NHOH, NO2, CN, CF3, CH2OR16, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3- cycloalkyl C7, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered heteroaryl, C7-C10 arylalkyl, C (>； = O) R16, C (>； = O) OR16, OC (>； = O) R16, C (>； = O) NR17R18, NR15C (>； = O) R16, NR15CO2R16, OC (>； = O) NR17R18, NR15C (>； = S) R16, SR16； S (>； = O) R16； S (>； = O) 2R16, and NR15S (>； = O) 2R16； alternatively, two R3 groups can be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group； R4 and R5 are H； R12 and R13 at each occurrence are each independently selected from H, C1-C6 alkyl substituted with 0-3 R20 and C6-C10 aryl substituted with 0-3 R20； alternatively, R12 and R13, together with the nitrogen to which they are attached, form a 3-7 membered heterocyclic ring substituted with 0-3 R20； R15 at each occurrence is independently selected from H and C1-C6 alkyl； R16 at each occurrence is independently selected from H, C1-C6 alkyl, and C6-C10 aryl； R17 and R1
